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Abstract Hypoxia is a critical hallmark of solid tumors and
involves enhanced cell survival, angiogenesis, glycolytic me-
tabolism, and metastasis. Hyperbaric oxygen (HBO) treatment
has for centuries been used to improve or cure disorders
involving hypoxia and ischemia, by enhancing the amount of
dissolved oxygen in the plasma and thereby increasing O2
delivery to the tissue. Studies on HBO and cancer have up to
recently focused on whether enhanced oxygen acts as a cancer
promoter or not. As oxygen is believed to be required for all the
major processes of wound healing, one feared that the effects
of HBO would be applicable to cancer tissue as well and
promote cancer growth. Furthermore, one also feared that
exposing patients who had been treated for cancer, to HBO,
would lead to recurrence. Nevertheless, two systematic
reviews on HBO and cancer have concluded that the use of
HBO in patients with malignancies is considered safe. To
supplement the previous reviews, we have summarized the
work performed on HBO and cancer in the period 2004–
2012. Based on the present as well as previous reviews, there
is no evidence indicating that HBO neither acts as a stimulator
of tumor growth nor as an enhancer of recurrence. On the other
hand, there is evidence that implies that HBO might have
tumor-inhibitory effects in certain cancer subtypes, and we
thus strongly believe that we need to expand our knowledge
on the effect and the mechanisms behind tumor oxygenation.
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Search terms
Pubmed was searched for articles concerning hyperbaric
oxygen (HBO) and cancer for the period from 2004 to
2012, using the MeSH search terms (“hyperbaric oxygena-
tion” and/or “hyperoxia” and “neoplasms”). A total of 28
articles were found relevant, directly involving the use of
HBO as a stand-alone or as adjuvant treatment on different
cancer types. We focused on growth, cell survival, angio-
genesis, and metastasis observed in HBO-treated cancers the
last 9 years, both as stand-alone and adjuvant treatment, and
compared them to older publications involving the selected
topic.
Background
Cancer and hypoxia
Solid tumors often contain areas subjected to acute or chron-
ic hypoxia [1], though with variable severity in patients both
within and among different tumor types [2]. Although se-
vere or prolonged hypoxia is deleterious, adaptation to the
hypoxic microenvironment has allowed cancer cells to sur-
vive and proliferate in this hostile milieu [3]. Tumor hypoxia
develops due to the structural and functional abnormalities
of the tumor vasculature since cancer growth often overrides
the ability of the cancer vasculature to adapt to the increas-
ing oxygen demand.
Traditionally, hypoxia was thought of as a factor limiting
cancer growth by reducing the ability of cells to divide.
However, more recently, hypoxia has proven to be a caus-
ative factor in many pathophysiological events, including
cancer progression. Multiple reports have demonstrated that
decreased oxygen tension selects for more malignant cells
and induces multiple cellular adaptations, which again sus-
tains and fosters cancer progression and thereby induces
cancer growth (Fig. 1). Hypoxia is reported to result in
cellular responses which improve oxygenation and viability
through induction of angiogenesis, an alteration in metabo-
lism by increased glycolysis and upregulation of genes
involved in cell survival/apoptosis [4]. Hypoxia has also
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been shown to increase genetic instability, activate invasive
growth, and preserve the undifferentiated cell state [1, 3].
Studies have demonstrated that hypoxia is implicated in the
resistance to conventional therapy [5]. Oxygen concentra-
tion has an especially crucial role in radiation oncology and
radiation resistance [6, 7]. The epithelial-to-mesenchymal
transition in cancer has been shown to be induced by hyp-
oxic conditions [8], leading to cancers with an invasive or
metastatic phenotype [9]. Given its important role as a
negative prognostics and predictive factor, hypoxia is con-
sidered as one of the best targets in cancer treatment.
The dual role of oxygen leads to the question: will lack of
oxygen inhibit cancer progression, or is hyperoxygenating
the tumor tissue the way to go in order to prevent cancer
growth and development?
Hyperbaric oxygen
Hyperbaric oxygen can be used to overcome hypoxia. HBO is
based on administration of 100 % oxygen at higher than
normal atmospheric pressure. HBO treatment enhances the
amount of dissolved oxygen in the plasma, thereby increasing
O2 tissue delivery independent of hemoglobin [10]. As in
normal tissue, the pO2 in cancer tissue increases significantly
during HBO exposure [11]. Thus, elevation of the tumor
oxygen pressure has been shown to be preserved clinically
for approximately 30 min after HBO exposure [12, 13]. HBO
therapy is today accepted and routinely used for many disor-
ders, related to both ischemia and/or hypoxia [10]. HBO is
considered safe and complications are rare using today’s stan-
dard treatment protocols. The Undersea and Hyperbaric Med-
ical Society has a list of approved indications for HBO therapy,
including decompression sickness, severe carbon monoxide
poisoning, nonhealing wounds, and late radiation injury.
As oxygen is believed to be required for all the major
processes involved in wound healing, including resistance
to infection, activation of fibroblasts, collagen deposition,
angiogenesis, and epithelization [14], it has been feared that
HBO would have a proliferative effect in cancers. Thus, for
many decades, the focus has been to elucidate if HBO
promotes cancer growth. In the early 2000s, both Feldmeier
et al. [15] and Daruwalla et al. [16] reviewed the literature
concerning HBO and cancer. The reviews included both
experimental and clinical studies using different types of
cancers, with and without additional therapy, and the results
showed varied responses. Nevertheless, the conclusion in
both reviews was that HBO did not promote cancer growth,
and that the use of HBO in patients with malignancies was
considered safe.
There are extensive studies on the effect of HBO on
normal tissue and wounds. Interestingly, evidence implies
that cancer tissue might differ in response from normal
tissue. The studies performed on HBO and cancer are com-
plex due to a wide range of experimental designs and
treatment regimes. Nevertheless, in an attempt to clarify
the differences in response to oxygenation, we have sum-
marized the literature concerning the effect of HBO on
crucial hallmarks of cancer, the effect of HBO on chemo-
and radiation therapy, and in addition we have clustered the
different cancer type responses.
HBO and cell survival
Studies of prolonged hyperoxia have shown that elevated
levels of reactive oxygen species (ROS) overwhelm the
antioxidant defense and lead to cellular damage and possible
organ dysfunction [17]. The tissue damage is found to be
dependent on the cell type, concentration of oxygen, and the
duration of the exposure. Gore et al. [17] have summarized
the molecular mechanisms behind hyperoxia-induced cell
death, revealing a complex signaling system including pro-
tein kinases and receptors such as RAGE, CXCR2, TLR3,
and TLR4.
Studies of apoptosis in neoplasms treated with HBO are
limited. Two in vitro studies on mammary and oral cancer
cells, respectively, showed no change in apoptosis after
HBO [18, 19]. On the other hand, Chen et al. [20] observed
activation of the pro-apoptotic pathway MAPK and down-
regulation of the anti-apoptotic ERK pathway in hemato-
poetic cells after HBO. Additionally, a study of HBO using
osteosarcoma cells also demonstrated induction of apoptosis
[21]. In two different animal models, gliomas and mammary
tumors, respectively, our group has demonstrated induction
of cell death after HBO treatment [22–24].
Furthermore, reduced cell proliferation, together with a
significant change in histology, has also been shown after
HBO treatment in DMBA-induced mammary tumors in
vivo [22, 24]. Granowitz et al. [18] observed the same
reduction in cell proliferation in their mammary in vitro
Fig. 1 Hypoxia is a hallmark of solid tumors. Summary of the
hypoxia-induced factors influencing cancer growth and progression
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study. In addition, two recent studies on osteosarcoma cells
[21] and nasopharyngeal carcinoma [25] support inhibition
of cell division after HBO treatment.
Together, this might imply that changes in oxygen con-
centration influence antioxidant pathways [26], leading to a
change in cell survival signaling. However, the picture is
complex, and mechanistic studies are required before any
final conclusions can be drawn.
HBO and angiogenesis
Today, angiogenesis is proposed to be a key factor for cancer
growth and metastasis. Thus, large experimental studies and
clinical trials have investigated the effect of antiangiogenic
therapies in the treatment of cancers. Since HBO in general
has been shown to promote cellular and vascular proliferation
in normal tissue and wounds (although the mechanisms are
not fully understood), it was assumed that it would also induce
angiogenesis in cancers. In contrary to what is expected and
addressed in the literature, HBO has been shown to induce an
antiangiogenic effect in two mammary tumor models [22, 24,
37], in addition to one glioma model [23]. Furthermore,
multiple studies showed no change in angiogenesis after
HBO treatment [27–32]. In his review, Feldmeier et al. [15]
thoroughly discussed oxygen and tumor angiogenesis, under-
lining the difference between cancer tissue and wounds and
concluded that HBO is not likely to enhance tumor angiogen-
esis. Thom [31] commented on the fact that the influence HBO
has on hypoxia-induced factor isoform expression appears to
vary with different tissues and possibly with chronology (e.g.,
looking early or late after wounding or an ischemic insult). We
believe it to be important to distinguish between normal or
injured tissue and tumor tissue when it comes to the effect of
HBO and angiogenesis since there is no evidence for enhanced
angiogenesis in cancerous tissue.
HBO and metastasis
In 1966, Johnson and Lauchlan first raised concern that
HBO might have metastatic potential [33]. However, it
was not possible to show a statistically significant increase
in the number of patients with distant metastasis, as the
number of patients in the series was too small. Nevertheless,
special attention was given to metastatic growth because the
first reports suggested that HBO might be affecting this part
of tumor progression [34]. Metastasis is a complex process
requiring multiple steps, including local tumor cell invasion,
entry into the blood or lymph vessels, and re-penetration and
colonization at a distant site [35]. Eventually, angiogenesis
is also required for distant metastasis to form.
So far, only observational studies have been performed,
and studies of the effect of HBO on the individual steps of
the metastatic process are still lacking [34]. None of the
studies reviewed showed induced metastasis after HBO [21,
36–39]. Furthermore, a recent study found HBO to induce a
mesenchymal-to-epithelial transition (MET) in DMBA-
induced mammary tumors, leading to a less aggressive
tumor type [24], thus indicating that oxygen might be a
key factor in MET [40]. This transition should lead to
cancers with a less invasive and metastatic phenotype.
HBO and chemotherapy
Hypoxia has been described as an important factor for
chemotherapeutic resistance [5]. Teicher [41] underlined
that the importance of hypoxia on the response to chemo-
therapy is highly drug dependent. However, hypoxia-
mediated chemoresistance has been ascribed to: (1) altered
cellular metabolism reducing drug cytotoxicity; (2) the re-
dox state, meaning that oxygen is required to generate ROS
to be maximally cytotoxic; and (3) genetic instability, which
can lead to more rapid development of drug-resistant cells.
In addition to the cytotoxicity, availability of the chemother-
apeutic drug in high enough dose is important to obtain a
maximal effect. Tumor tissue anatomy influences transport
of intravenously injected substances to the cancer cells, and
thus determines the efficacy of the drug.
Al-Waili et al. [42] summarized the potential role of HBO
in combination with conventional therapies. They hypothe-
sized that HBO could improve and help overcome chemo-
therapeutic resistance by increasing both tumor perfusion
and cellular sensitivity [42].
Studies on HBO as a chemotherapeutic adjuvant have
shown augmented effects both in vitro [18, 21, 25, 43] and
in vivo [21, 44–47], although the mechanism(s) are not
known. Heys et al. [28] studied the effect of HBO on chemo-
therapy in a clinical setting, using HBO as a pretreatment to
improve vascularity, and thereby improve the effect of che-
motherapy. However, HBO did not increase the neovascular-
ity, and they correlated the lack of chemotherapeutic
potentiation to this. In a mammary tumor model, Moen et al.
[48] found that the uptake of chemotherapy is increased for
the duration of, and immediately after, HBO treatment. Based
on this study, potentiation of chemotherapy can probably not
occur unless the chemotherapeutic agent is administered dur-
ing or immediately after the HBO session, when the pO2 is
elevated. Another study by Moen et al. [24], on the same
mammary tumor model, found altered genetic expression after
HBO indicating a change to less tumorigenic metabolism,
possibly influencing the chemotherapeutic response. Many
have ascribed the enhanced chemotherapeutic effect after
HBO to increased levels of ROS. Moen et al. [48], however,
found no change in MDA levels after HBO, indicating that in
this study ROS levels cannot be the main determinant of an
increased chemotherapeutic effect. Microarray studies have
made it possible to classify breast cancers at the molecular
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level [49, 50] and correlate their signatures with metastatic
behavior and clinical outcome, and thereby making it easier to
develop targeted therapy. Underlining the importance of
breast cancer subtyping, it is important to comment on the
differences between different tumor models: Moen et al. [48]
found an increased uptake of the chemotherapeutic drug 5-FU
into DMBA-induced tumors after HBO, while Jevne et al.
[51] failed to find the same correlation in the 4T1 mammary
tumor model.
The combination of HBO and chemotherapy has also been
tried in other cancer types. Suzuki et al. [44] suggest that HBO
therapy prolongs the biological residence time of carboplatin
in glioma patients. However, there are still uncertainties
concerning the mechanisms of action of HBO on the efficacy
of carboplatin. The same group found that HBO enhanced
transendothelial permeability in rat brains and HBO might
therefore be favorable for the uptake and therefore also the
effect of carboplatin [52]. Preliminary results from a small,
clinical study, on nonsmall cell lung cancer, show promising
results when combining hyperthermia and HBO with pacli-
taxel and carboplatin [45]. However, they emphasize that the
study lacks proper controls, and thereby the additional value
of HBO to the chemohyperthermia response cannot be made.
Kawasoe et al. [21] found, both in vitro and in vivo, that HBO
enhanced the chemotherapeutic effect of carboplatin in osteo-
sarcomas. Furthermore, combining HBO and cisplatin signif-
icantly reduced tumor volume in a human ovarian cancer
xenograft model [46].
It is, however, important to underline that Mayer et al.
[53] list up five chemotherapeutic agents (doxorubicin,
bleomycin, disulfiram, cisplatin, and mafenide acetate); all
of which are strongly contradictory in combination with
HBO due to potential potentiation of toxicity [54]. Of the
reviewed papers, only Heys et al. [28] and Selvendiran et al.
[46] have utilized the listed chemotherapeutics in combina-
tion with HBO.
Relating the knowledge on the different chemotherapeutics
in relation to cancer subtypes will be important for further
studies and for development of therapies and adjuvant thera-
pies. In addition, proper randomized studies are necessary in
order to be able to make any final conclusions regarding the
effect of HBO in combination with chemotherapy.
HBO and radiotherapy
Radiotherapy in combination with HBO has been used clini-
cally in two different applications: (1) as a therapeutic agent
for treating late radiation injury and (2) as a radiosensitizer,
aiming to increase the effect of radiotherapy [53]. In this
review, we focus only on the latter application of HBO.
Gray et al. [6] proved in the 1950s that the oxygen
concentration influences the effect of radiotherapy and the
influence of hypoxic modification in relation to radiotherapy
has been extensively studied since then. In 2011, Overgaard
published a meta-analysis reviewing the influence of hyp-
oxic modification of radiotherapy in head and neck carcino-
ma [7]. Overall, Overgaard found that out of the various
hypoxic modification techniques, HBO showed the most
pronounced effect [7], and thus will improve the results of
radiotherapy. Nevertheless, in a recent and extensive review
by Bennett et al. [55], the authors have also reviewed the
effect of radiotherapy in combination with HBO. They
concluded that there is some evidence that HBO improves
local tumor control and mortality in tumors of the head and
neck; however, the outcomes seem to be related to the use of
unusual fractionation schemes, and Bennett et al. [55] there-
by conclude that the benefits of HBO should be interpreted
with caution.
It has also been shown that adverse side effects like
oxygen poisoning and severe tissue radiation injury is asso-
ciated with the use of HBO in combination with radiother-
apy [55]. However, it is important to emphasize the
importance of timing of HBO exposure in relation to the
radiation [53]. Kohshi et al. [56] found that to avoid haz-
ardous side effects, irradiation should be administered im-
mediately after and not concurrently to HBO treatment. It
has been shown that euoxic conditions persist for some time
after HBO exposure due to postponed oxygen saturation and
washout kinetics [12, 13]. Thus, a change in protocols could
possibly reduce or prevent serious side effects, and thereby
justify the use of HBO in radiosensitization [53]. A conclu-
sion regarding the use of HBO in combination with radio-
therapy still remains unclear.
HBO and cancer types
This review summarizes the work performed on HBO and
cancer during the last 9 years (Table 1) and supports the
previous findings [15, 16] since none of the studies reported
a cancer-promoting effect of HBO. However, we have
changed the focus to whether HBO might have an inhibitory
effect on cancer growth. The variety of responses observed
in cancers after HBO treatment supports what we know
today, i.e., that no single treatment of any kind will be
efficient in all types of cancers. However, could the treat-
ment be efficient in some cancer types? And if so, why do
we observe these differences?
HBO and breast cancer
Breast cancer is the most frequently occurring cancer in
women and comprises 22.8 % of cancer incidence in
females worldwide [57]. Granowitz et al. [18] showed that
HBO treatment alone had a strong antiproliferative effect on
different mammary cancer cells in vitro. They suggested that
236 Targ Oncol (2012) 7:233–242
T
ab
le
1
S
tu
di
es
on
th
e
ef
fe
ct
of
hy
pe
rb
ar
ic
ox
yg
en
(H
B
O
)
an
d
m
al
ig
na
nc
y,
bo
th
al
on
e
an
d
in
co
m
bi
na
tio
n
w
ith
co
nv
en
tio
na
l
tr
ea
tm
en
t,
fr
om
20
01
to
20
12
S
tu
dy
Y
ea
r
Ty
pe
of
st
ud
y
C
an
ce
r
ty
pe
H
B
O
pr
ot
oc
ol
A
dd
iti
on
al
th
er
ap
y
H
B
O
pe
r
se
C
om
bo
th
er
ap
y
M
et
as
ta
si
s
A
ng
io
ge
ne
si
s
B
re
as
t
ca
nc
er
S
tu
hr
et
al
.
[4
7]
20
04
In
vi
vo
D
M
B
A
-i
nd
uc
ed
m
am
m
ar
y
tu
m
or
s
in
ra
ts
0.
2
M
P
a,
4
ex
p
at
90
m
in
,
11
da
ys
or
7
ex
p,
23
da
ys
5-
F
U
↓
↓
G
ra
no
w
itz
et
al
.
[1
8]
20
05
In
vi
tr
o
M
am
m
ar
y
ce
lls
fr
om
no
rm
al
ep
ith
el
ia
,
pr
im
ar
y
tu
m
or
,
an
d
m
et
as
ta
tic
tu
m
or
+
hu
m
an
M
C
F
7
ce
ll
lin
e
0.
24
M
P
a
M
el
ph
al
an
,
ge
m
ci
ta
bi
ne
,
an
d
pa
cl
ita
xe
l
↓
↓
H
ey
s
et
al
.
[2
8]
20
06
C
lin
ic
al
L
oc
al
ly
ad
va
nc
ed
br
ea
st
ca
rc
in
om
a
0.
24
/0
.2
M
P
a,
90
m
in
da
ily
(5
/w
ee
k)
fo
r
10
da
ys
C
yc
lo
ph
os
ph
am
id
e,
do
xo
ru
bi
ci
n,
an
d
vi
nc
ri
st
in
e
↔
↔
R
aa
et
al
.
[2
2]
20
07
In
vi
vo
D
M
B
A
-i
nd
uc
ed
m
am
m
ar
y
tu
m
or
s
in
ra
ts
H
yp
er
ox
ia
(1
00
%
O
2
)
or
0.
15
M
P
a,
4
ex
p
at
90
m
in
ov
er
11
da
ys
5-
F
U
↓
↓
↓
H
ar
oo
n
et
al
.
[3
6]
20
07
In
vi
vo
M
ou
se
m
am
m
ar
y
ad
en
oc
ar
ci
no
m
a
4T
1-
G
F
P
ce
ll
lin
e
in
nu
/n
u
m
ic
e
0.
28
M
P
a
fo
r
45
m
in
da
ily
(5
/w
ee
k)
up
to
5
w
ee
ks
↓
M
oe
n
et
al
.
[2
4]
20
09
In
vi
vo
D
M
B
A
-i
nd
uc
ed
m
am
m
ar
y
tu
m
or
s
in
ra
ts
0.
2
M
P
a,
4
ex
p
at
90
m
in
,
11
da
ys
↓
↓
M
oe
n
et
al
.
[4
8]
20
09
In
vi
vo
D
M
B
A
-i
nd
uc
ed
m
am
m
ar
y
tu
m
or
s
in
ra
ts
0.
2
M
P
a,
4
ex
p
at
90
m
in
ov
er
11
da
ys
or
1
ex
p
at
90
m
in
5-
F
U
↓
Je
vn
e
et
al
.
[5
1]
20
11
In
vi
vo
M
ur
in
e
4T
1
m
am
m
ar
y
tu
m
or
s
in
N
O
D
/S
C
ID
m
ic
e
0.
25
M
P
a,
3
ex
p
at
90
m
in
ov
er
8
da
ys
5-
F
U
↔
↓
M
oe
n
et
al
.
[3
7]
20
12
In
vi
vo
M
ur
in
e
4T
1
m
am
m
ar
y
tu
m
or
s
in
N
O
D
/S
C
ID
m
ic
e
0.
25
M
P
a,
90
m
in
ex
p,
3
in
te
rm
itt
en
t
or
7
da
ily
ex
p
ov
er
8
da
ys
↓
(↔
/↑
)
↓/
↔
P
ro
st
at
e
ca
nc
er
C
ho
ng
et
al
.[
29
]
20
04
In
vi
vo
H
um
an
pr
os
ta
te
(L
N
C
aP
)
ce
lls
in
im
m
un
od
ef
ic
ie
nt
m
ic
e
0.
23
6
M
P
a,
20
ex
p
at
90
m
in
,
5/
w
ee
k
fo
r
4
w
ee
ks
↔
(↓
)
↔
T
an
g
et
al
.
[3
1]
20
09
In
vi
vo
H
um
an
pr
os
ta
te
P
C
-3
ce
lls
in
im
m
un
od
ef
ic
ie
nt
m
ic
e
0.
2
M
P
a,
20
ex
p
at
90
m
in
,
5/
w
ee
k
fo
r
4
w
ee
ks
↔
↔
T
an
g
et
al
.
[3
2]
20
09
In
vi
vo
H
um
an
pr
os
ta
te
ca
nc
er
L
N
C
aP
ce
lls
in
im
m
un
od
ef
ic
ie
nt
m
ic
e
0.
2
M
P
a,
20
ex
p
at
90
m
in
,
5/
w
ee
k
fo
r
4
w
ee
ks
↔
↔
C
ol
or
ec
ta
l
ca
nc
er
H
je
ld
e
et
al
.[
66
]
20
05
In
vi
tr
o
T
ra
di
tio
na
l
ce
ll
ca
rc
in
om
a
(A
Y
-2
7)
,
H
um
an
pr
im
ar
y
co
lo
na
de
no
ca
rc
in
om
a
(W
iD
r)
an
d
hu
m
an
co
lo
na
de
no
ca
rc
in
om
a
ce
ll
lin
e
(S
W
48
0)
0.
1,
0.
2,
0.
3,
an
d
0.
4
M
P
a
O
2
fo
r
30
m
in
P
ho
to
dy
na
m
ic
th
er
ap
y
↔
D
ar
uw
al
la
et
al
.
[3
8]
20
06
In
vi
vo
D
im
et
hy
lh
yd
ra
zi
ne
in
du
ce
d
pr
im
ar
y
co
lo
n
ca
rc
in
om
a
ce
ll
lin
e
in
m
ic
e
0.
24
M
P
a,
90
m
in
da
ily
ex
p
fo
r
7,
13
,
19
,
an
d
25
da
ys
↓/
↑
↔
(↔
)
D
ar
uw
al
la
et
al
.
[3
9]
20
07
In
vi
vo
P
ri
m
ar
y
co
lo
n
ca
rc
in
om
a
ce
ll
lin
e
in
m
ic
e
0.
24
M
P
a,
5
tim
es
à
90
m
in
ov
er
9
da
ys
S
M
A
–
pi
ra
ru
bi
ci
n
↔
↓
↓
G
lio
m
as
O
ga
w
a
et
al
.
[7
6]
20
06
C
lin
ic
al
P
at
ie
nt
s
w
ith
hi
gh
gr
ad
e
gl
io
m
as
0.
28
M
P
a,
30
-6
0
m
in
R
ad
io
th
er
ap
y
an
d
pr
oc
ar
ba
zi
ne
,
ni
m
us
tin
e,
an
d
vi
nc
ri
st
in
e
↔
/↓
S
tu
hr
et
al
.
[2
3]
20
07
In
vi
vo
B
T
4C
ra
t
gl
io
m
a
xe
no
gr
af
ts
in
nu
de
ra
ts
10
0
%
O
2
or
0.
2
M
P
a
H
B
O
,
3
ex
p
at
90
m
in
ov
er
8
da
ys
↓
↓
K
oh
sh
i
et
al
.
[7
5]
20
07
C
lin
ic
al
P
at
ie
nt
s
w
ith
an
ap
la
st
ic
as
tr
oc
yt
om
a
an
d
gl
io
bl
as
to
m
a
m
ul
tif
or
m
e
0.
25
M
P
a,
60
m
in
R
ad
io
th
er
ap
y
(p
re
vi
ou
s
ch
em
ot
he
ra
py
)
↔
/↓
S
uz
uk
i
et
al
.
[4
4]
20
09
C
lin
ic
al
P
at
ie
nt
s
w
ith
re
cu
rr
en
t
m
al
ig
na
nt
or
br
ai
ns
te
m
gl
io
m
as
0.
2
M
P
a,
60
m
in
du
ri
ng
i.v
.
ad
m
.
of
ca
rb
op
la
tin
+
24
h
af
te
r
dr
ug
ad
m
C
ar
bo
pl
at
in
↓
O
th
er
C
he
n
et
al
.
[2
0]
20
07
In
vi
tr
o
H
um
an
le
uk
em
ia
(J
ur
ka
t)
,
m
ul
tip
le
m
ye
lo
m
a
(N
C
l-
H
92
9)
,
ca
rc
in
om
a
0.
25
or
0.
35
M
P
a
ox
yg
en
or
ai
r
fo
r
2–
12
h
↓/
↔
Targ Oncol (2012) 7:233–242 237
HBO could be an effective therapy for breast cancer. This is
supported by six different animal studies performed during
the last 9 years, using clinically relevant HBO protocols.
These revealed a significant inhibitory effect of HBO as a
stand-alone treatment on mammary tumor growth in vivo
[22, 24, 37, 47, 48, 51] (Table 1). Feldmeier et al. [15] and
Daruwalla et al. [16] reviewed three older studies on mam-
mary tumors and HBO, all in the same C3H mouse model,
where none of them found effects on tumor growth [58–60].
However, they did not consider an extensive study from
1964 in their reviews, where Kluft et al. [61] reported that
HBO retarded growth of a transplanted mammary carcino-
ma (TM 8013) growing in C 57 black mice.
As the main focus in the older studies was to confirm or
reject HBO as cancer promoter, most studies focused only
on cancer growth and metastasis. Nevertheless, several re-
cent studies, showing cancer inhibitory effects, have gone
into more detail. As previously mentioned, HBO has been
shown to induce an antiangiogenic effect in two mammary
tumor models [22, 48, 51]. Furthermore, an increase in cell
death and reduced cell proliferation, together with a signif-
icant change in histology, has also been shown after HBO
treatment in DMBA-induced mammary tumors in vivo [22,
24]. In relation to metastasis, it has been shown that HBO
induced MET in DMBA-induced mammary tumors, leading
to a less aggressive tumor type [24]. In a 4T1 mammary
tumor model, Haroon et al. [36] found that HBO restricts the
growth of large tumor cell colonies. Moen et al. [37] found
lung metastasis in the same tumor model after HBO, thus
HBO here did not hinder metastasis. However, they lack
comparable endpoint controls and therefore a conclusion as
to whether there would be less colonies could not be drawn.
Despite a significant number of animal studies, no clin-
ical trials on HBO and breast cancer per se have been
performed and only one small clinical study on combined
treatment is available. With this background, we conclude
that the effect of HBO should be further explored in breast
cancer subtypes, especially focusing on the possible effect
of HBO as an adjuvant tumor therapy.
HBO and head and neck cancer
The National Cancer Institute defines head and neck cancer
as a neoplasm that arises in the nasal cavity, sinuses, lips,
mouth, salivary glands, throat, or larynx [62]. Only one
study has been performed during recent years, where HBO
has been studied in combination with radiotherapy in exper-
imental head and neck carcinoma in mice [27] (Table 1).
They found that even though HBO did reduce the hypoxic
state of the tumors, it did not have any effect on tumor
growth, neither alone nor in combination with radiotherapy
[27]. Furthermore, they did not find evidence of enhanced
angiogenesis in the tumors after HBO treatment, neitherTa
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when staining for CD31 nor measuring VEGF expression,
supporting the notion that HBO does not induce angiogen-
esis in tumors.
As previously stated, Bennett et al. [55] reviewed the
effect of combining HBO with radiotherapy. Even though
studies have shown beneficial results on local tumor control,
mortality, and local tumor recurrence, the protocols of the
reviewed literature made them conclude that they could not
justify the routine use of HBO in combination with radiation
[55]. However, as discussed in “HBO and radiotherapy,” the
conclusion within the field of HBO and radiosensitization
has not yet reached a consensus.
HBO and colorectal cancer
Colorectal cancer is a disease originating from the epithe-
lial cells lining the colon or rectum of the gastrointestinal
tract [63]. Most colorectal cancers occur due to lifestyle
and increasing age with only a minority of cases associ-
ated with underlying genetic disorders [64]. Even though
surgery can be curative if the disease is caught early,
additional treatment of advanced colorectal cancer is com-
monly in use [63].
Several studies have examined the effect of HBO con-
comitant with other therapies in colorectal cancer. In an
older clinical study, Dische and Senanayake [65] demon-
strated positive results when combining HBO and radiother-
apy on patients with carcinoma in the colon and the rectum.
Hjelde et al. [66] studied the effect of hyperoxia in combi-
nation with photodynamic therapy on three different colon
carcinomas in vitro (Table 1). They concluded that hyper-
oxia did not increase the occurrence of cell death after
photodynamic therapy. However, older experimental and
clinical studies have demonstrated that HBO improves the
effect of photodynamic therapy [67–71]. Thus, the lack of
response in the study by Hjelde et al. [66] might be ascribed
to lack of hypoxic cells in the in vitro experimental setup.
Additionally, two papers by Daruwalla et al. [38, 39] exam-
ine the effect of HBO in two different in vivo colon tumor
models (Table 1). In the first paper, the effect of HBO per se
was studied [38]. Here, they concluded firstly that HBO did
not have any tumor stimulatory effect and does not promote
formation of distal metastases, and secondly that HBO
therefore can safely be used in combination with other
therapies. Furthermore, they performed experiments on an
in vivo model of primary colon carcinoma with HBO both
alone and in combination with styrene maleic acid (SMA)–
pirarubicin [39]. Again, they concluded that HBO alone
gave no effects. However, HBO in combination with
SMA–pirarubicin gave a reduction both in liver metastases
and tumor growth, in addition to inducing increased levels
of necrosis. Thus, HBO as a stand-alone treatment seems to
have no effect on colorectal cancer, but as a treatment
adjuvant, HBO seems to be an interesting alternative and
its potential use should be explored further.
HBO and gliomas
Gliomas are tumors originating in the glial cells in the
brain or the spine. Patients with high-grade gliomas
generally have poor prognosis [72], and the illness is
rarely curable. Designing therapy is challenging due to
the neoplasm’s infiltrative nature, resistance to apoptosis,
and recurrence and resistance to therapy [73]. In 2011,
Beppu et al. [74] reviewed the effect of HBO on glio-
mas. However, the review only exists in Japanese, and
thus is not commented on.
In 2007, Stuhr et al. [23] published an experimental
study, examining the effect of HBO on the growth and
development of rat glioma xenografts per se (Table 1). They
found that increased levels of pO2, using both normobaric
and moderate HBO, significantly reduced tumor growth,
possibly by increasing cell death and reducing the vascular
density. This might indicate that HBO alone has a favorable
effect on gliomas. However, it is important to underline that
the experimental tumors were implanted in the neck and not
in the brain, and this may well have influenced the outcome
of the experiments.
Further, only three other papers in the period 2004–
2012 have been published utilizing HBO on gliomas
(Table 1). They are all preliminary clinical studies, inves-
tigating HBO in combination with radiotherapy and che-
motherapy [44, 75, 76]. Kohshi et al. [75] and Ogawa et
al. [76] both conclude that there is a possible advantage to
combining HBO with radiotherapy, but they also underline
the need for further investigation within this field. Special
caution should be taken when interpreting the results from
the study by Koshi et al. [75], as anaplastic astrocytomas
are included in the trial and compared with the patients
with glioblastoma mulitforme.
In a study of HBO and chemotherapy, Suzuki et al. [44]
suggest that HBO therapy prolongs the biological residence
time of carboplatin. However, the mechanisms of action of
HBO on the clinical efficacy of carboplatin are still un-
known. Some evidence implies that HBO as an adjuvant
to traditional therapy in gliomas should be investigated
further, and this could lead to an improvement of current
therapy regimens.
HBO and leukemia
Leukemia is cancer of the blood or bone marrow character-
ized by an abnormal increase of immature white blood cells
[77]. Two recent in vitro experiments have shown promising
results when treating leukemia cells with HBO [20, 43]
(Table 1). In addition, Tonomura and Granowitz [78], in
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an editorial in 2007, have commented on the effect of
HBO on leukemia. They concluded that since HBO pro-
motes apoptosis in leukemia cells, it should be further
exploited as a novel treatment for leukemia. It is, howev-
er, important to emphasize that this is based on experi-
ments performed in cell culture, and thus needs further
validation from in vivo models to exclude the possibility
that this is just an in vitro phenomenon. In two older
experiments, studies were performed on HBO using ani-
mal leukemia model systems [79, 80]. In neither of the in
vivo experiments were differences observed in growth rate
or metastasis after HBO treatment. However, the limited
number of studies might therefore call for further investi-
gation with regard to the use of HBO in leukemia.
HBO and prostate cancer
Cancer of the prostate gland is the second most frequent type
of cancer inmenworldwide, accounting for 13.6% of all cases
[57]. Treatment of prostate cancer depends on the grade of the
disease. As most prostate cancers are slow growing, some
cancers are not treated at all. However, aggressive cancers
are normally treated using surgery, in addition to chemother-
apy, hormonal therapy, immunotherapy, and/or radiation.
Three animal studies have been published recently on HBO
as stand-alone treatment of prostate cancer (Table 1). Neither
Chong et al. [29] nor Tang et al. [81, 32] found any change in
in vivo tumor growth after HBO treatment. None of the path-
ological characteristics, such as microvessel density, differen-
tiation status, proliferation, or apoptosis, were changed. In
addition, Kalns et al. [82, 83] published two papers in the late
1990s where they showed that HBO can decrease the rate of
growth and increase the sensitivity to the anticancer agents
taxol and doxorubicin in in vitro experiments, by accumulating
prostate cancer cells in the chemosensitive portion of the cell
cycle. Further studies on in vivo prostate cancermodels and the
effect of HBO as an adjuvant to chemotherapy are evidently
necessary before any definite conclusions can be made.
HBO and cervical cancer and bladder cancer
Cervical cancer of the female reproductive system represents
8.8 % of cancer incidence in women and bladder cancer 3.0 %
in both sexes [57]. Based on ten clinical studies, Daruwalla et
al. [16] stated that HBO treatment of patients with cervical and
bladder cancer did not offer any improved benefit or improved
outcome. The older clinical trials, combining HBO and radio-
therapy, generally showed no change in cancer growth or
survival. This is presumably the reason why no new studies
have been performed on the effect of HBO on these cancer
types. Thus, neither cervical cancer nor bladder cancer seems
to be good candidates for demonstration of an improved effect
of traditional therapy in combination with HBO.
Comments and future work
The consensus today is that research performed hitherto has
failed to demonstrate that HBO has a cancer-promoting effect
or that it enhances recurrence. Nevertheless, both recent and
older research studies have shown that HBO can be inhibitory
and reduce cancer growth in some cancer types, like breast
cancer. On the other hand, cervical and bladder cancers appear
to be nonresponders to HBO. In vitro studies have confirmed
that there are discrepancies in growth fractions between dif-
ferent cancer cell lines following exposure to hyperoxia [10].
Thus, this supports the need for performing randomized stud-
ies on HBO as a stand-alone treatment or in combination with
other therapies for certain cancer types or subtypes.
The observed variety in response to HBO found during
the last decades can be ascribed to both differences in types
of cancers but also to the large variety in HBO treatment
protocols. Thus, differences in response to oxygen between
different cancer types should not lead to an exclusion of
HBO as a form of cancer treatment or as a cancer treatment
adjuvant for selected types of cancers. Further research on
HBO and its effect on certain types of cancer and studies on
the underlying mechanisms involved are therefore needed.
To clarify if tumor hypoxia is as important for cancer
progression as indicated in the literature, HBO can be used
as an important research tool. Concomitant studies of hyper-
oxia (“the flip of the coin”) and hypoxia might be valuable
and can give us additional and important information on
how oxygen influences cancer growth and metastasis. We
therefore strongly believe that we need to expand our un-
derstanding of what happens during oxygenation of cancer
tissue and we need to examine in depth the effect of hyper-
oxia on different cancer types and subtypes.
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